Magenta Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is developing therapeutics to transform hematopoietic stem cell transplants for patients with immune and blood-based diseases. It maintains a platform with integrated and modular approach, which aims to reboot the blood and immune systems. The Company’s products include MGTA-145, MGTA-456, E478, and G100. The Company also developing a pipeline of small molecules; biologics, including antibody drug conjugates; and a cell therapy, which transplant options for many more patients with autoimmune diseases, blood cancers and genetic diseases. The Company’s C100 program targets HSCs, immune cells, and disease-causing cells, the C200 program targets HSCs and disease-causing cells and the C300 program targets only immune cells. This is achieved by tuning the antibodies to specific cellular markers or receptors that are expressed on the particular cell types.
Market Cap:550.5M; Shares Outstanding:39M; Short Interest: 6.06%; Q3 2019(9/30/19): Cash 161M. Loss 20.99M
EPS and Sales:
|Date||EPS||% last year||% last quarter|
Total institutions: 78，no change
Shares hold: 24765k shares. no change
shares% hold: 63.52%，no change